Skip Navigation

Cardiovascular Research 2006 71(4):615-617; doi:10.1016/j.cardiores.2006.07.001
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Feng, Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feng, Q.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Beyond erythropoiesis: The anti-inflammatory effects of erythropoietin

Qingping Feng*

Departments of Medicine, Physiology and Pharmacology, University of Western Ontario, Centre for Critical Illness Research, Lawson Health Research Institute, 800 Commissioners Road, London, Ontario, Canada N6A 4G5

* Tel.: +1 519 685 8300x55443; fax: +1 519 685 8341. Email address: qfeng@uwo.ca

Received 4 July 2006; accepted 7 July 2006

The first 10% of the full text of this article appears below.

See article by Li et al. [4] (pages 684–694) in this issue.


   1. Cardioprotective effects of EPO
 
Erythropoietin (EPO) is a 30.4-kDa glycoprotein essential for red blood cell production. In adults, EPO is produced primarily in the kidney via an oxygen-sensing mechanism and stimulates erythroid progenitors in the bone marrow to increase red blood cell mass. In addition to its role in erythropoiesis, EPO has been shown to protect against ischemic injury in several organs including the heart. In various animal models, administration of EPO reduces infarct size and improves cardiac function following myocardial ischemia and reperfusion (I/R). The protective effects have been observed regardless of whether EPO was administered before ischemia, at the onset of ischemia, or at reperfusion [1,2]. . . [Full Text of this Article]


   2. Anti-inflammatory effects of EPO
 

   3. Signaling mechanisms of EPO in the heart
 

   4. Clinical significance
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?